超深度测序血浆游离DNA早期检测转移性复发并监测尿路上皮膀胱癌患者疗效
研究纳入68例局部晚期膀胱癌患者,采用超深度测序(中位105,000×)检测血浆游离DNA(ctDNA),在诊断时、化疗期间、膀胱切除术前及监测期间共采集656份血浆样本。结果显示ctDNA在诊断时具有高度预后价值(HR 29.1,P=.001),膀胱切除术后监测可100%敏感度、98%特异度识别转移性复发,较影像学中位提前96天。
要点
- 诊断时化疗前ctDNA存在与预后高度相关(HR 29.1,P=.001)。
- 膀胱切除术后ctDNA监测识别转移性复发敏感度100%、特异度98%,较影像学中位提前96天。
- 高危患者化疗期间ctDNA动态与疾病复发相关(P=.023),而病理降期不相关。
核心结论
- ctDNA评估用于膀胱癌早期风险分层、治疗监测和早期复发检测是可行的,并为评估早期治疗干预的临床研究提供了基础。
研究设计与样本
- 研究纳入68例局部晚期膀胱癌患者,通过全外显子测序鉴定患者特异性体细胞突变,采用超深度测序(中位105,000×)检测血浆DNA中的循环肿瘤DNA(ctDNA)。
- 在诊断时、化疗期间、膀胱切除术前及监测期间共采集656份血浆样本,并进行肿瘤亚型和免疫特征表达谱分析。
主要发现
- 诊断时化疗前ctDNA存在具有高度预后价值(风险比29.1;P=.001)。
- 膀胱切除术后,ctDNA分析在疾病监测期间正确识别所有转移性复发患者(敏感度100%,特异度98%),较影像学中位提前96天。
- 对于高危患者(治疗前或治疗期间ctDNA阳性),化疗期间ctDNA动态与疾病复发相关(P=.023),而病理降期不相关。
- 肿瘤中心生物标志物分析显示,突变过程(特征5)与病理降期相关(P=.024);肿瘤亚型、DNA损伤应答突变和其他生物标志物无显著相关性。
临床怎么用
- 作者认为,ctDNA分析与其他可用方法相比与治疗疗效的关联更好。
- 作者结论指出,ctDNA评估用于膀胱癌早期风险分层、治疗监测和早期复发检测是可行的,并为评估早期治疗干预的临床研究提供了基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. PATIENTS AND METHODS: We included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep sequencing (median, 105,000×) of plasma DNA. Plasma samples (n = 656) were procured at diagnosis, during chemotherapy, before cystectomy, and during surveillance. Expression profiling was performed for tumor subtype and immune signature analyses. RESULTS: Presence of ctDNA was highly prognostic at diagnosis before chemotherapy (hazard ratio, 29.1; P = .001). After cystectomy, ctDNA analysis correctly identified all patients with metastatic relapse during disease monitoring (100% sensitivity, 98% specificity). A median lead time over radiographic imaging of 96 days was observed. In addition, for high-risk patients (ctDNA positive before or during treatment), the dynamics of ctDNA during chemotherapy was associated with disease recurrence (P = .023), whereas pathologic downstaging was not. Analysis of tumor-centric biomarkers showed that mutational processes (signature 5) were associated with pathologic downstaging (P = .024); however, no significant correlation for tumor subtypes, DNA damage response mutations, and other biomarkers was observed. Our results suggest that ctDNA analysis is better associated with treatment efficacy compared with other available methods. CONCLUSION: ctDNA assessment for early risk stratification, therapy monitoring, and early relapse detection in bladder cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interventions.
引用
- Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019. PMID: 31059311. doi:10.1200/JCO.18.02052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。